[1]
|
Siegel, R.L., Miller, K.D., Wagle, N.S. and Jemal, A. (2023) Cancer Statistics, 2023. CA: A Cancer Journal for Clinicians, 73, 17-48. https://doi.org/10.3322/caac.21763
|
[2]
|
Gu, X.Y., Zheng, R.S., Zhang, S.W., Zeng, H.M., Sun, K.X. and Zou, X.N. (2018) Analysis on the Trend of Prostate Cancer Incidence and Age Change in Cancer Registration Areas of China, 2000 to 2014. Chinese Journal of Preventive Medicine, 52, 586-592.
|
[3]
|
Han, S., Liu, F. and Xing, N. (2022) Analysis of the Incidence Trend of Prostate Cancer in China’s Cancer Registry Areas from 1988 to 2015. Chinese Journal of Urology, No.1, 51-55.
|
[4]
|
Alghamdi, D., Kernohan, N., Li, C. and Nabi, G. (2023) Comparative Assessment of Different Ultrasound Technologies in the Detection of Prostate Cancer: A Systematic Review and Meta-Analysis. Cancers, 15, Article 4105. https://doi.org/10.3390/cancers15164105
|
[5]
|
Xiong, F., Wang, H., Li, F. and Xue, L. (2023) Application of Transrectal Ultrasound Con-Trast-Enhanced Microvascular Imaging, Elastic Imaging and Conventional Ultra-Sound-Targeted Guided Prostate Cancer Puncture Biopsy in the Diagnosis of Prostate Le-Sions. Journal of Modern Urology, 1-5.
|
[6]
|
Yi, A., Kim, J.K., Park, S.H., Kim, K.W., Kim, H.S., Kim, J.H., et al. (2006) Contrast-Enhanced Sonography for Prostate Cancer Detection in Patients with Indeterminate Clinical Findings. American Journal of Roentgenology, 186, 1431-1435. https://doi.org/10.2214/ajr.04.1959
|
[7]
|
Maxeiner, A., Fischer, T., Schwabe, J., Baur, A.D.J., Stephan, C., Peters, R., et al. (2018) Contrast-Enhanced Ultrasound (CEUS) and Quantitative Perfusion Analysis in Patients with Suspicion for Prostate Cancer. Ultraschall in der Medizin-European Journal of Ultrasound, 40, 340-348. https://doi.org/10.1055/a-0594-2093
|
[8]
|
Nong, W., Huang, Q. and Gao, Y. (2023) Development and Validation of a Nomogram for Predicting Prostate Cancer Based on Combining Contrast-Enhanced Transrectal Ultrasound and Biparametric MRI Imaging. Frontiers in Oncology, 13, Article 1275773. https://doi.org/10.3389/fonc.2023.1275773
|
[9]
|
Wei, C., Li, C., Szewczyk-Bieda, M., Upreti, D., Lang, S., Huang, Z., et al. (2018) Performance Characteristics of Transrectal Shear Wave Elastography Imaging in the Evaluation of Clinically Localized Prostate Cancer: A Prospective Study. Journal of Urology, 200, 549-558. https://doi.org/10.1016/j.juro.2018.03.116
|
[10]
|
O’Keefe, D.S., Bacich, D.J., Huang, S.S. and Heston, W.D.W. (2018) A Perspective on the Evolving Story of PSMA Biology, PSMA-Based Imaging, and Endoradiotherapeutic Strategies. Journal of Nuclear Medicine, 59, 1007-1013. https://doi.org/10.2967/jnumed.117.203877
|
[11]
|
Wondergem, M., Van Der Zant, F.M., Broos, W.A.M., Roeleveld, T.A., Donker, R., ten Oever, D., et al. (2020) 18F-DCFPyL PET/CT for Primary Staging in 160 High-Risk Prostate Cancer Patients; Metastasis Detection Rate, Influence on Clinical Management and Preliminary Results of Treatment Efficacy. European Journal of Nuclear Medicine and Molecular Imaging, 48, 521-531. https://doi.org/10.1007/s00259-020-04782-2
|
[12]
|
Ulaner, G.A., Thomsen, B., Bassett, J., Torrey, R., Cox, C., Lin, K., et al. (2022) 18F-DCFPyL PET/CT for Initially Diagnosed and Biochemically Recurrent Prostate Cancer: Prospective Trial with Pathologic Confirmation. Radiology, 305, 419-428. https://doi.org/10.1148/radiol.220218
|
[13]
|
Jansen, B.H.E., Bodar, Y.J.L., Zwezerijnen, G.J.C., Meijer, D., Van Der Voorn, J.P., Nieuwenhuijzen, J.A., et al. (2020) Pelvic Lymph-Node Staging with 18F-DCFPyL PET/CT Prior to Extended Pelvic Lymph-Node Dissection in Primary Prostate Cancer-The Salt Trial-. European Journal of Nuclear Medicine and Molecular Imaging, 48, 509-520. https://doi.org/10.1007/s00259-020-04974-w
|
[14]
|
Chu, C.E., Alshalalfa, M., Sjöström, M., Zhao, S.G., Liu, Y., Chou, J., et al. (2021) Prostate-Specific Membrane Antigen and Fluciclovine Transporter Genes Are Associated with Variable Clinical Features and Molecular Subtypes of Primary Prostate Cancer. European Urology, 79, 717-721. https://doi.org/10.1016/j.eururo.2021.03.017
|
[15]
|
Sprute, K., Kramer, V., Koerber, S.A., Meneses, M., Fernandez, R., Soza-Ried, C., et al. (2020) Diagnostic Accuracy of 18F-DCFPyL PET/CT Imaging for Lymph Node Staging of Prostate Carcinoma in Primary and Biochemical Recurrence. Journal of Nuclear Medicine, 62, 208-213. https://doi.org/10.2967/jnumed.120.246363
|
[16]
|
Schollhammer, R., Robert, G., Asselineau, J., Yacoub, M., Vimont, D., Balamoutoff, N., et al. (2022) Comparison of 68Ga-PSMA-617 PET/CT and68Ga-RM2 PET/CT in Patients with Localized Prostate Cancer Who Are Candidates for Radical Prostatectomy: A Prospective, Single-Arm, Single-Center, Phase II Study. Journal of Nuclear Medicine, 64, 379-385. https://doi.org/10.2967/jnumed.122.263889
|
[17]
|
Surasi, D.S., Eiber, M., Maurer, T., Preston, M.A., Helfand, B.T. and Josephson, D. (2023) Diagnostic Performance and Safety of Positron Emission Tomography with 18F-rhPSMA-7.3 in Patients with Newly Diagnosed Unfavourable Intermediate-to Very-High-Risk Prostate Cancer: Results from a Phase 3, Prospective, Multicentre Study (LIGHTHOUSE). European Urology, 84, 361-370. https://doi.org/10.1016/j.eururo.2023.06.018
|
[18]
|
Schmidt-Hegemann, N., Eze, C., Li, M., Rogowski, P., Schaefer, C., Stief, C., et al. (2018) Impact of 68Ga-PSMA PET/CT on the Radiotherapeutic Approach to Prostate Cancer in Comparison to CT: A Retrospective Analysis. Journal of Nuclear Medicine, 60, 963-970. https://doi.org/10.2967/jnumed.118.220855
|
[19]
|
van Leeuwen, P.J., Donswijk, M., Nandurkar, R., Stricker, P., Ho, B., Heijmink, S., et al. (2019) Gallium‐68‐Prostate‐Specific Membrane Antigen (68Ga‐PSMA) Positron Emission Tomography (PET)/Computed Tomography (CT) Predicts Complete Biochemical Response from Radical Prostatectomy and Lymph Node Dissection in Intermediate‐ and High‐Risk Prostate Cancer. BJU International, 124, 62-68. https://doi.org/10.1111/bju.14506
|
[20]
|
Farolfi, A., Ceci, F., Castellucci, P., Graziani, T., Siepe, G., Lambertini, A., et al. (2018) 68Ga-PSMA-11 PET/CT in Prostate Cancer Patients with Biochemical Recurrence after Radical Prostatectomy and PSA<0.5 ng/ml. Efficacy and Impact on Treatment Strategy. European Journal of Nuclear Medicine and Molecular Imaging, 46, 11-19. https://doi.org/10.1007/s00259-018-4066-4
|
[21]
|
Cornford, P., van den Bergh, R.C.N., Briers, E., Van den Broeck, T., Cumberbatch, M.G., De Santis, M., et al. (2021) EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II—2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer. European Urology, 79, 263-282. https://doi.org/10.1016/j.eururo.2020.09.046
|
[22]
|
Yakar, D., Noordzij, W. and Kwee, T.C. (2019) Potential Causes of False-Negative Interpretations in 68Ga-PSMA PET/CT for the Detection of Local and Recurrent Prostate Cancer. Clinical Nuclear Medicine, 45, e32-e35. https://doi.org/10.1097/rlu.0000000000002750
|
[23]
|
Witkowska-Patena, E., Giżewska, A., Miśko, J. and Dziuk, M. (2019) 18F-Prostate-Specific Membrane Antigen 1007 and 18F-FCH PET/CT in Local Recurrence of Prostate Cancer. Clinical Nuclear Medicine, 44, e401-e403. https://doi.org/10.1097/rlu.0000000000002556
|
[24]
|
Witkowska-Patena, E., Giżewska, A., Dziuk, M., Miśko, J., Budzyńska, A. and Walęcka-Mazur, A. (2019) Head-to-Head Comparison of 18F-Prostate-Specific Membrane Antigen-1007 and 18F-Fluorocholine PET/CT in Biochemically Relapsed Prostate Cancer. Clinical Nuclear Medicine, 44, e629-e633. https://doi.org/10.1097/rlu.0000000000002794
|
[25]
|
Rosar, F., Schaefer-Schuler, A., Bartholomä, M., Maus, S., Petto, S., Burgard, C., et al. (2022) [89Zr]Zr-PSMA-617 PET/CT in Biochemical Recurrence of Prostate Cancer: First Clinical Experience from a Pilot Study Including Biodistribution and Dose Estimates. European Journal of Nuclear Medicine and Molecular Imaging, 49, 4736-4747. https://doi.org/10.1007/s00259-022-05925-3
|
[26]
|
Fanti, S., Goffin, K., Hadaschik, B.A., Herrmann, K., Maurer, T., MacLennan, S., et al. (2020) Consensus Statements on PSMA PET/CT Response Assessment Criteria in Prostate Cancer. European Journal of Nuclear Medicine and Molecular Imaging, 48, 469-476. https://doi.org/10.1007/s00259-020-04934-4
|
[27]
|
Turkbey, B., Rosenkrantz, A.B., Haider, M.A., Padhani, A.R., Villeirs, G., Macura, K.J., et al. (2019) Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2. European Urology, 76, 340-351. https://doi.org/10.1016/j.eururo.2019.02.033
|
[28]
|
Brembilla, G., Dell’Oglio, P., Stabile, A., Damascelli, A., Brunetti, L., Ravelli, S., et al. (2020) Interreader Variability in Prostate MRI Reporting Using Prostate Imaging Reporting and Data System Version 2.1. European Radiology, 30, 3383-3392. https://doi.org/10.1007/s00330-019-06654-2
|
[29]
|
Emmett, L., Buteau, J., Papa, N., Moon, D., Thompson, J., Roberts, M.J., et al. (2021) The Additive Diagnostic Value of Prostate-Specific Membrane Antigen Positron Emission Tomography Computed Tomography to Multiparametric Magnetic Resonance Imaging Triage in the Diagnosis of Prostate Cancer (PRIMARY): A Prospective Multicentre Study. European Urology, 80, 682-689. https://doi.org/10.1016/j.eururo.2021.08.002
|
[30]
|
Sigle, A., Borkowetz, A., von Hardenberg, J., Drerup, M., Kornienko, K., Kwe, J., et al. (2023) Prediction of Significant Prostate Cancer in Equivocal Magnetic Resonance Imaging Lesions: A High-Volume International Multicenter Study. European Urology Focus, 9, 606-613. https://doi.org/10.1016/j.euf.2023.01.020
|
[31]
|
Wang, S., Kozarek, J., Russell, R., Drescher, M., Khan, A., Kundra, V., et al. (2024) Diagnostic Performance of Prostate-Specific Antigen Density for Detecting Clinically Significant Prostate Cancer in the Era of Magnetic Resonance Imaging: A Systematic Review and Meta-Analysis. European Urology Oncology, 7, 189-203. https://doi.org/10.1016/j.euo.2023.08.002
|
[32]
|
Rajwa, P., Pradere, B., Quhal, F., Mori, K., Laukhtina, E., Huebner, N.A., et al. (2021) Reliability of Serial Prostate Magnetic Resonance Imaging to Detect Prostate Cancer Progression during Active Surveillance: A Systematic Review and Meta-Analysis. European Urology, 80, 549-563. https://doi.org/10.1016/j.eururo.2021.05.001
|
[33]
|
Chen, M., Zhang, Q., Zhang, C., Zhao, X., Marra, G., Gao, J., et al. (2018) Combination of 68Ga-PSMA PET/CT and Multiparametric MRI Improves the Detection of Clinically Significant Prostate Cancer: A Lesion-by-Lesion Analysis. Journal of Nuclear Medicine, 60, 944-949. https://doi.org/10.2967/jnumed.118.221010
|
[34]
|
Eklund, M., Jäderling, F., Discacciati, A., et al. (2021) MRI-Targeted Biopsy in Prostate Cancer Screening. The New England Journal of Medicine, 385, 2109-2110. https://doi.org/10.1056/NEJMoa2100852
|
[35]
|
Gandaglia, G., Ploussard, G., Valerio, M., Mattei, A., Fiori, C., Roumiguié, M., et al. (2020) The Key Combined Value of Multiparametric Magnetic Resonance Imaging, and Magnetic Resonance Imaging-Targeted and Concomitant Systematic Biopsies for the Prediction of Adverse Pathological Features in Prostate Cancer Patients Undergoing Radical Prostatectomy. European Urology, 77, 733-741. https://doi.org/10.1016/j.eururo.2019.09.005
|
[36]
|
Ahdoot, M., Lebastchi, A.H., Long, L., Wilbur, A.R., Gomella, P.T., Mehralivand, S., et al. (2022) Using Prostate Imaging-Reporting and Data System (PI-RADS) Scores to Select an Optimal Prostate Biopsy Method: A Secondary Analysis of the Trio Study. European Urology Oncology, 5, 176-186. https://doi.org/10.1016/j.euo.2021.03.004
|
[37]
|
Qi, Y., Zhang, S., Wei, J., Zhang, G., Lei, J., Yan, W., et al. (2019) Multiparametric MRI‐Based Radiomics for Prostate Cancer Screening with PSA in 4-10 ng/ml to Reduce Unnecessary Biopsies. Journal of Magnetic Resonance Imaging, 51, 1890-1899. https://doi.org/10.1002/jmri.27008
|
[38]
|
Lu, Y., Li, B., Huang, H., Leng, Q., Wang, Q., Zhong, R., et al. (2022) Biparametric MRI-Based Radiomics Classifiers for the Detection of Prostate Cancer in Patients with PSA Serum Levels of 4∼10 ng/ml. Frontiers in Oncology, 12, Article 1020317. https://doi.org/10.3389/fonc.2022.1020317
|
[39]
|
Basso Dias, A., Mirshahvalad, S.A., Ortega, C., Perlis, N., Berlin, A., van der Kwast, T., et al. (2023) The Role of [18F]-DCFPyL PET/MRI Radiomics for Pathological Grade Group Prediction in Prostate Cancer. European Journal of Nuclear Medicine and Molecular Imaging, 50, 2167-2176. https://doi.org/10.1007/s00259-023-06136-0
|
[40]
|
Wang, W., Pan, B., Ai, Y., Li, G., Fu, Y. and Liu, Y. (2024) ParaCM-PNet: A CNN-Tokenized MLP Combined Parallel Dual Pyramid Network for Prostate and Prostate Cancer Segmentation in MRI. Computers in Biology and Medicine, 170, 107999. https://doi.org/10.1016/j.compbiomed.2024.107999
|
[41]
|
Sushentsev, N., Rundo, L., Abrego, L., Li, Z., Nazarenko, T., Warren, A.Y., et al. (2023) Time Series Radiomics for the Prediction of Prostate Cancer Progression in Patients on Active Surveillance. European Radiology, 33, 3792-3800. https://doi.org/10.1007/s00330-023-09438-x
|
[42]
|
Hou, Y., Jiang, K., Wang, L., Zhi, R., Bao, M., Li, Q., et al. (2023) Biopsy-Free AI-Aided Precision MRI Assessment in Prediction of Prostate Cancer Biochemical Recurrence. British Journal of Cancer, 129, 1625-1633. https://doi.org/10.1038/s41416-023-02441-5
|
[43]
|
Papp, L., Rausch, I., Hacker, M. and Beyer, T. (2019). Fuzzy Radiomics: A Novel Approach to Minimize the Effects of Target Delineation on Radiomic Models. Nuklearmedizin, 58, 107-108. https://doi.org/10.1055/s-0039-1683478
|
[44]
|
Grahovac, M., Spielvogel, C.P., Krajnc, D., Ecsedi, B., Traub-Weidinger, T., Rasul, S., et al. (2023) Machine Learning Predictive Performance Evaluation of Conventional and Fuzzy Radiomics in Clinical Cancer Imaging Cohorts. European Journal of Nuclear Medicine and Molecular Imaging, 50, 1607-1620. https://doi.org/10.1007/s00259-023-06127-1
|